Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOK) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 41,700 shares, a growth of 7.8% from the January 15th total of 38,700 shares. Based on an average daily trading volume, of 34,200 shares, the days-to-cover ratio is presently 1.2 days. Approximately 2.9% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Evoke Pharma in a report on Sunday. They issued a “sell” rating on the stock.

Evoke Pharma Price Performance

Shares of EVOK stock traded down $0.16 during trading hours on Tuesday, hitting $5.21. The stock had a trading volume of 13,877 shares, compared to its average volume of 9,590. The stock’s 50-day moving average price is $4.65 and its two-hundred day moving average price is $4.82. Evoke Pharma has a one year low of $3.54 and a one year high of $12.32. The stock has a market capitalization of $7.76 million, a price-to-earnings ratio of -0.47 and a beta of 0.16.

Institutional Trading of Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.